Search clinical trials for: Human Plasma Protein

Total 47879 results

Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial (PALETTE)

Sepsis
Octapharma

Recruiting

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Acute Hereditary Angio Edema

Romania
Wageningen University
FrieslandCampina

Recruiting

Milk and Plant Protein Digestion (MAPP-D)

Food Digestion

Netherlands
National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada
Octapharma

Not yet recruiting

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

Acquired Antithrombin Deficiency
Yao Liu

Recruiting

Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma

Lymphoma | Multiple Myeloma

China
Hoffmann-La Roche

Recruiting

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, Denmark, Spain, Australia, Italy, New Zealand, France, Canada, Germany
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, Denmark, United States, Spain, Australia, Japan, France, Korea, Republic of, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, United Kingdom, Czechia, Germany, Poland
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Multiple Myeloma | Plasma Cell Leukemia

China
SCRI Development Innovations, LLC
Janssen Research & Development, LLC

Recruiting

Outpatient Administration of Teclistamab for Multiple Myeloma

Multiple Myeloma

United States
Qilu Pharmaceutical Co., Ltd.

Recruiting

A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Northside Hospital, Inc.
Blood and Marrow Transplant Group of Georgia

Not yet recruiting

CAR T-cell Therapy in Patients With Renal Dysfunction

Multiple Myeloma | Acute Lymphoblastic Leukemia, Adult | Non-hodgkin Lymphoma,B Cell

United States
Mayo Clinic

Recruiting

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Caribou Biosciences, Inc.

Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage)

Relapsed/Refractory Multiple Myeloma

United States
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
University of Alberta
Social Sciences and Humanities Research Council of Canada

Recruiting

LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study (LONGEVITI)

Melanoma | Cancer | Breast Cancer | Multiple Myeloma | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Chronic Leukemia | Tyrosine Kinase Mutation

Canada
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...

Recruiting

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Multiple Myeloma

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
Janssen Research & Development, LLC

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

Multiple Myeloma

Belgium, Korea, Republic of, Australia, United Kingdom, France, Sweden, Spain, Turkey, Italy, Czechia, Brazil, Netherlands, Poland, Switzerland, Norway, Germany
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)

Relapsed or Refractory Multiple Myeloma

United States, Austria, Denmark, Canada, Australia, China, Spain, Germany, United Kingdom, Hungary, Taiwan, Israel, Japan, India, Norway, Brazil, Italy, Greece, Korea, Republic of, Colombia, Singapore, Netherlands, Argentina, Hong Kong, Romani... and more
Kite, A Gilead Company

Recruiting

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)

Relapsed/Refractory Waldenstrom Macroglobulinemia | Relapsed/Refractory Richter Transformation | Relapsed/Refractory Burkitt Lymphoma | Relapsed/Refractory Hairy Cell Leukemia

United States, Spain, Germany, Italy, France, Netherlands, Switzerland, Austria
Emory University
National Cancer Institute (NCI)

Recruiting

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects With R/R MM

Multiple Myeloma

China
Chunrui Li
Nanjing IASO Biotherapeutics Co.,Ltd

Recruiting

A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma

Extramedullary Multiple Myeloma

China
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Multiple Myeloma

China
Biomea Fusion Inc.

Recruiting

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Lymphoma | Lymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Cancer | Progression | Multiple Myeloma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Plasma Cell Myeloma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Refractory | Myeloma, Plasma-Cell | Myelomatosis | Acute Mixed-Phenotype...

United States, Spain, Netherlands, Greece, Italy
Memorial Sloan Kettering Cancer Center
Pentixapharm AG

Recruiting

In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET

Multiple Myeloma | Non-Hodgkin Lymphoma | Erdheim-Chester Disease | Rosai-Dorfman Disease | Histiocytic Neoplasms

United States
Nanjing IASO Biotherapeutics Co.,Ltd

Recruiting

A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (FUMANBA-1)

Multiple Myeloma

China
Hamad Medical Corporation

Recruiting

Effect of Human Plasma Protein Transfusion With and Without Crystalloids During Major Liver Resection Surgeries

Coagulation; Intravascular | Fluid Electrolyte Disorders

Qatar
Marcela V. Maus, M.D.,Ph.D.

Recruiting

TriPRIL CAR T Cells in Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
Xinqiao Hospital of Chongqing
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Refractory

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

Multiple Myeloma

Belgium, Korea, Republic of, Denmark, United Kingdom, Australia, New Zealand, Italy, Spain, France
Fred Hutchinson Cancer Center
medac GmbH

Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Myeloid Leukemia | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Anaplastic Large Cell Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Prolymphocytic Leukemia | Refractory... and other conditions

United States
Melissa Bates
Department of Health and Human Services

Recruiting

Sleep Apnea in Patients With MGUS and MM

Multiple Myeloma | Monoclonal Gammopathy of Undetermined Significance

United States
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng... and other collaborators

Recruiting

Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
Janssen Research & Development, LLC

Recruiting

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)

Hematological Malignancies

United States, Netherlands, Spain, France, Sweden
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Recurrent T-Cell... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
Abdullah Khan

Terminated

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Novartis Pharmaceuticals

Active, not recruiting

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Belgium, Italy, Korea, Republic of, Hong Kong, Israel, Finland, Spain, Japan, United States
National Cancer Institute (NCI)

Withdrawn

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
Sanguine Biosciences

Completed

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Depression | Melanoma | Epilepsy | Lymphoma | Multiple Sclerosis | Kidney Cancer | Cervical Cancer | Diabetes Mellitus | Leukemia | Breast Cancer | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Parkinson's Disease | Systemic Lupus Erythematosus | Multiple Myeloma | Hepatitis B | Insomnia | Colorectal Cancer | HIV/AID... and other conditions

United States
Shanghai Henlius Biotech

Active, not recruiting

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

Multiple Myeloma

China
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Multiple Myeloma

United States, Puerto Rico
Masonic Cancer Center, University of Minnesota

Active, not recruiting

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Acute Myeloid Leukemia | Hodgkin Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Acute Lymphocytic Leukemia | Chronic Myelogenous Leukemia | Myelodysplasia | Relapsed T-Cell Lymphoma | Relapsed Large Cell Lymphoma | Biphenotypic/Undifferentiated Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Precancerous/Nonmalignant Condition

Search clinical trials for: Human Plasma Protein

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations